Patients who responded optimally to the approach significantly improved glycaemic control, insulin resistance, and reduced IGF-1 availability, controlling and reducing the serum concentration of markers associated with increased risk of Barrett’s esophagus evolution towards adenocarcinoma. This evidence concerns the gene IGF1 and adenocarcinoma.